Latest revenue
$12.5M
as of 2026-03-31
Latest net income
$-2.1M
as of 2026-03-31
Net margin
-16.9%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think APYX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $156.2M
- Enterprise value
- $169.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 12.17×
- Dividend yield
- 0.0%
- 52-wk high
- $4.68
- 52-wk low
- $1.59
- Beta
- —
- Shares out
- 34.6M
5-year trend
What this company does
ITEM 1. Business General Apyx Medical Corporation (“Company”, “Apyx Medical”, “we”, “us”, or “our”) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760. We are a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring SystemTM (“AYON”) in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results.…
AI summary unavailable — showing raw filing excerpt
Generated from APYX's filing dated 2026-03-10
Key risks
ITEM 1A. Risk Factors In addition to risks and uncertainties in the ordinary course of business, important risk factors that may affect us are discussed below. Additional risks not presently known to us, or that we currently believe are immaterial, may also significantly impact or impair our business operations. Risks Relating to Our Business We manufacture the majority of our products at our Clearwater, Florida and Sofia, Bulgaria facilities. Components, labor-intensive assemblies and sub-assemblies, and sterilization services are outsourced to third parties and produced to our specifications. We are also dependent on OEM customers who have no legal obligation to purchase products from us.…
AI summary unavailable — showing raw filing excerpt
Generated from APYX's filing dated 2026-03-10
Profitability
Gross margin
62.5%
2.4%Operating margin
-12.2%
68.9%Net margin
-21.2%
56.5%Return on equity
-77.1%
53.3%Return on assets
-16.8%
53.6%Leverage
Debt / equity
3.60×
0.9%Long-term debt / equity
2.40×
0.5%Debt / assets
78.2%
0.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $12.5M | +32.4% | $-2.1M | +49.2% | -16.9% |
Q4 2025 2025-12-31 | $19.2M | +34.7% | $-1.3M | +71.9% | -6.8% |
Q3 2025 2025-09-30 | $12.9M | +12.1% | $-2.0M | +57.8% | -15.4% |
Q2 2025 2025-06-30 | $11.4M | -6.4% | $-3.8M | +42.4% | -33.2% |
Q1 2025 2025-03-31 | $9.4M | -7.9% | $-4.2M | +45.2% | -44.0% |
Q4 2024 2024-12-31 | $14.2M | — | $-4.6M | — | -32.5% |
Q3 2024 2024-09-30 | $11.5M | -4.1% | $-4.7M | -1.6% | -40.9% |
Q2 2024 2024-06-30 | $12.1M | -10.5% | $-6.6M | -559.6% | -54.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on APYX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns APYX
Institutional value
$41.5M
Total shares held
11.3M
Distinct holders
34
-25 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | ROYCE & ASSOCIATES LP | 2.6M | $9.6M | +168.2K (+6.9%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.6M | $5.7M | — | New |
| 3 | AIGH Capital Management LLC | 1.1M | $4.1M | +0 (+0.0%) | No change |
| 4 | Silverberg Bernstein Capital Management LLC | 1.0M | $3.8M | +8.1K (+0.8%) | Added |
| 5 | ESSEX INVESTMENT MANAGEMENT CO LLC | 901.4K | $3.3M | — | New |
| 6 | COMMONWEALTH EQUITY SERVICES, LLC | 649.1K | $2.4M | -14.5K (-2.2%) | Trimmed |
| 7 | SEI INVESTMENTS CO | 598.3K | $2.2M | +448.2K (+298.6%) | Added |
| 8 | BlackRock, Inc. | 527.7K | $1.9M | +16.8K (+3.3%) | Added |
| 9 | Taylor Frigon Capital Management LLC | 414.6K | $1.5M | -23.4K (-5.3%) | Trimmed |
| 10 | EAM Investors, LLC | 246.4K | $909.3K | +0 (+0.0%) | No change |
| 11 | Huntleigh Advisors, Inc. | 245.9K | $907.4K | +9.5K (+4.0%) | Added |
| 12 | UBS Group AG | 231.3K | $853.7K | +229.9K (+16078.0%) | Added |
| 13 | Kingsview Wealth Management, LLC | 208.8K | $770.4K | +20.6K (+10.9%) | Added |
| 14 | VANGUARD FIDUCIARY TRUST CO | 202.7K | $747.9K | — | New |
| 15 | Hillsdale Investment Management Inc. | 174.3K | $643.2K | +79.8K (+84.4%) | Added |
| 16 | JANE STREET GROUP, LLC | 131.3K | $484.5K | -36.9K (-22.0%) | Trimmed |
| 17 | Z3 Capital Partners, LLC | 93.1K | $343.4K | +3.0K (+3.3%) | Added |
| 18 | SALEM INVESTMENT COUNSELORS INC | 91.0K | $335.8K | +45.5K (+100.0%) | Added |
| 19 | Hudson Bay Capital Management LP | 54.0K | $199.3K | +33.3K (+160.6%) | Added |
| 20 | PERKINS CAPITAL MANAGEMENT INC | 42.0K | $155.0K | -43.0K (-50.6%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once APYX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.